Simulations Plus (SLP) Set to Announce Quarterly Earnings on Thursday

Simulations Plus (NASDAQ:SLP) will likely be posting its Q4 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $0.09 per share and revenue of $17.44 million for the quarter. Interested persons may visit the company’s upcoming Q4 2026 earnings report for the latest details on the call scheduled for Friday, October 30, 2026 at 4:00 PM ET.

Simulations Plus Price Performance

SLP stock opened at $18.50 on Thursday. Simulations Plus has a twelve month low of $11.09 and a twelve month high of $21.01. The stock has a market capitalization of $374.16 million, a price-to-earnings ratio of 46.25 and a beta of 1.31. The firm’s fifty day simple moving average is $18.44 and its two-hundred day simple moving average is $17.14.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on SLP shares. Weiss Ratings restated a “sell (d+)” rating on shares of Simulations Plus in a report on Tuesday, October 6th. BTIG Research reiterated a “neutral” rating on shares of Simulations Plus in a report on Wednesday, October 7th. Seven analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $17.25.

About Simulations Plus

Simulations Plus, Inc develops software and provides services that support pharmaceutical research, drug development and regulatory decision-making. Its technologies help scientists model how drug compounds behave in the body, assess formulation and delivery characteristics, and evaluate potential safety and efficacy outcomes.

The company’s software portfolio includes GastroPlus, a platform for physiologically based pharmacokinetic and pharmacodynamic modeling; ADMET Predictor, which forecasts absorption, distribution, metabolism, excretion and toxicity properties; and DDDPlus, which simulates drug dissolution and dosage-form performance.